Published in Blood on August 26, 2004
Cancer in dyskeratosis congenita. Blood (2009) 4.28
Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev (2010) 3.24
Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell (2012) 2.26
Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood (2006) 1.82
Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol (2006) 1.76
SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood (2013) 1.68
Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst (2008) 1.36
Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. Cancer Res (2010) 1.26
Diagnosis of Fanconi anemia in patients with bone marrow failure. Haematologica (2009) 1.25
Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J Clin Invest (2010) 1.13
Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation--implications for screening and HPV vaccination. Biol Blood Marrow Transplant (2008) 1.11
Dental Perspective of Rare Disease of Fanconi Anemia: Case Report with Review. Clin Med Insights Case Rep (2016) 1.04
Continuous in vivo infusion of interferon-gamma (IFN-gamma) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice. Blood (2006) 1.03
HLA-matched related donor hematopoietic cell transplantation in 43 patients with Fanconi anemia conditioned with 60 mg/kg of cyclophosphamide. Biol Blood Marrow Transplant (2007) 1.02
Fanconi anemia: young patients at high risk for squamous cell carcinoma. Mol Cell Pediatr (2014) 1.00
Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol (2014) 1.00
GS-nitroxide (JP4-039)-mediated radioprotection of human Fanconi anemia cell lines. Radiat Res (2011) 0.99
Overnight transduction with foamyviral vectors restores the long-term repopulating activity of Fancc-/- stem cells. Blood (2008) 0.99
The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma. Mutat Res (2013) 0.95
High incidence of HPV-associated head and neck cancers in FA deficient mice is associated with E7's induction of DNA damage through its inactivation of pocket proteins. PLoS One (2013) 0.90
Natural history and management of Fanconi anemia patients with head and neck cancer: A 10-year follow-up. Laryngoscope (2015) 0.88
Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia. Haematologica (2014) 0.88
Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines. Klin Padiatr (2012) 0.86
Fanconi anemia and the cell cycle: new perspectives on aneuploidy. F1000Prime Rep (2014) 0.86
Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting. Mol Ther (2011) 0.84
The use of haematopoietic stem cell transplantation in Fanconi anaemia patients: a survey of decision making among families in the US and Canada. Health Expect (2013) 0.83
The Fanconi anemia pathway has a dual function in Dickkopf-1 transcriptional repression. Proc Natl Acad Sci U S A (2014) 0.82
Preemptive Bone Marrow Transplantation for FANCD1/BRCA2. Biol Blood Marrow Transplant (2015) 0.82
Intraoral Mitochondrial-Targeted GS-Nitroxide, JP4-039, Radioprotects Normal Tissue in Tumor-Bearing Radiosensitive Fancd2(-/-) (C57BL/6) Mice. Radiat Res (2016) 0.80
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biol Blood Marrow Transplant (2016) 0.79
Fanconi anemia - learning from children. Pediatr Rep (2011) 0.79
Programmable bio-nanochip-based cytologic testing of oral potentially malignant disorders in Fanconi anemia. Oral Dis (2015) 0.79
Haemopoietic stem cell transplantation for genetic disorders. Arch Dis Child (2005) 0.79
Cancer stem cells are enriched in Fanconi anemia head and neck squamous cell carcinomas. Int J Oncol (2014) 0.78
RAD51C--a new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC). Oral Oncol (2013) 0.78
Preemptive Bone Marrow Transplantation and Event-Free Survival in Fanconi Anemia. Biol Blood Marrow Transplant (2016) 0.78
DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One (2014) 0.77
The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant (2016) 0.77
Detection of human papillomavirus in the oral cavities of persons with Fanconi anemia. Oral Dis (2014) 0.77
Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia. Pediatr Transplant (2011) 0.77
Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned. Haematologica (2015) 0.77
Neonatal manifestations of inherited bone marrow failure syndromes. Semin Fetal Neonatal Med (2015) 0.77
Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers. Clin Cancer Res (2015) 0.76
An internal pilot design for prospective cancer screening trials with unknown disease prevalence. Trials (2015) 0.75
Interleukin 8/KC enhances G-CSF induced hematopoietic stem/progenitor cell mobilization in Fancg deficient mice. Stem Cell Investig (2014) 0.75
Secondary Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation in Childhood. Children (Basel) (2015) 0.75
Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation (HCT) for Inherited Bone Marrow Failure Syndromes (IBMFS): Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75
Evolution of malignant plasmacytoma cell lines from K14E7 Fancd2-/- mouse long-term bone marrow cultures. Oncotarget (2016) 0.75
Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Inherited Bone Marrow Failure Syndromes (IBMFS): Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75
Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia. Vaccine (2017) 0.75
Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med (2004) 7.73
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature (2010) 6.95
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet (2006) 4.98
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol (2010) 4.67
Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol (2008) 4.41
Hematotoxicity in workers exposed to low levels of benzene. Science (2004) 4.19
TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet (2008) 4.12
Cancer incidence in persons with Fanconi anemia. Blood (2002) 4.05
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood (2006) 3.84
Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood (2005) 3.71
Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev (2010) 3.24
Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica (2007) 3.03
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood (2013) 2.82
The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood (2006) 2.82
Umbilical cord blood transplantation: the first 25 years and beyond. Blood (2013) 2.79
Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica (2008) 2.72
Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica (2005) 2.66
Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol (2011) 2.49
Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol (2009) 2.48
Dyskeratosis congenita. Hematol Oncol Clin North Am (2009) 2.45
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood (2007) 2.36
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
Occupational exposure to formaldehyde, hematotoxicity, and leukemia-specific chromosome changes in cultured myeloid progenitor cells. Cancer Epidemiol Biomarkers Prev (2010) 2.34
Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell (2012) 2.26
Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood (2013) 2.12
Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in Dyskeratosis congenita. Hum Genet (2013) 2.10
Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. Blood (2002) 2.08
Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation. Transplantation (2012) 2.07
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol (2012) 2.05
Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature (2011) 2.03
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood (2002) 2.03
Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood (2008) 2.01
Fanconi anemia. Semin Hematol (2006) 1.99
Shwachman-Diamond syndrome: report from an international conference. J Pediatr (2002) 1.99
Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood (2011) 1.99
Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita. Genes Dev (2011) 1.98
Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood (2013) 1.91
Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood (2011) 1.89
Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood (2002) 1.83
Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis (2002) 1.79
Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant (2012) 1.72
Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood (2012) 1.69
Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood (2013) 1.68
Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am J Hum Genet (2007) 1.67
p53 protein overexpression in bone marrow biopsies of patients with Shwachman-Diamond syndrome has a prevalence similar to that of patients with refractory anemia. Arch Pathol Lab Med (2002) 1.64
Cancer in Fanconi anemia. Blood (2003) 1.63
Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab (2007) 1.63
Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging (Albany NY) (2010) 1.62
Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol (2012) 1.60
Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood (2003) 1.59
Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood (2007) 1.58
Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol (2004) 1.56
The role of telomere biology in bone marrow failure and other disorders. Mech Ageing Dev (2007) 1.56
Ethical reappraisal of 15 years of cord-blood transplantation. Lancet (2003) 1.55
Association of HLA-E polymorphism with severe bacterial infection and early transplant-related mortality in matched unrelated bone marrow transplantation. Transplantation (2005) 1.52
Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med (2003) 1.51
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood (2011) 1.50
Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood (2003) 1.49
Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood (2004) 1.47
Ocular and orbital manifestations of the inherited bone marrow failure syndromes: Fanconi anemia and dyskeratosis congenita. Ophthalmology (2009) 1.47
Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood (2003) 1.45
All in the family: disclosure of "unwanted" information to an adolescent to benefit a relative. Am J Med Genet A (2008) 1.44
Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood (2002) 1.41
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica (2007) 1.39
Primary Epstein-Barr virus infection with pneumonia transmitted by allogeneic bone marrow after transplantation. Clin Infect Dis (2006) 1.39
Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol (2007) 1.37
Frequency and natural history of inherited bone marrow failure syndromes: the Israeli Inherited Bone Marrow Failure Registry. Haematologica (2010) 1.36
Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst (2008) 1.36
Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol Blood Marrow Transplant (2009) 1.32
The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report. Support Cancer Ther (2006) 1.30
Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica (2006) 1.27
Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica (2010) 1.27
Diagnosis of Fanconi anemia in patients with bone marrow failure. Haematologica (2009) 1.25
Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica (2007) 1.24
Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant (2011) 1.24
Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections. Haematologica (2010) 1.23
How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel. Am J Med Genet A (2011) 1.23
Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer (2009) 1.22
Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica (2005) 1.21
Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia. Transplantation (2006) 1.21
CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. Blood (2002) 1.19
Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood (2004) 1.18
Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Transplantation (2013) 1.18
Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol (2010) 1.17
Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation. Cancer (2008) 1.17
MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease. Blood (2009) 1.17
Polymorphisms in cytokine and cellular adhesion molecule genes and susceptibility to hematotoxicity among workers exposed to benzene. Cancer Res (2005) 1.16
Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant (2010) 1.15
Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. Biol Blood Marrow Transplant (2010) 1.15
Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseases. Best Pract Res Clin Haematol (2010) 1.15